BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

565 related articles for article (PubMed ID: 18280748)

  • 21. Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia.
    Romanski A; Bug G; Becker S; Kampfmann M; Seifried E; Hoelzer D; Ottmann OG; Tonn T
    Exp Hematol; 2005 Mar; 33(3):344-52. PubMed ID: 15730858
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways.
    Verhoeven DH; de Hooge AS; Mooiman EC; Santos SJ; ten Dam MM; Gelderblom H; Melief CJ; Hogendoorn PC; Egeler RM; van Tol MJ; Schilham MW; Lankester AC
    Mol Immunol; 2008 Sep; 45(15):3917-25. PubMed ID: 18657862
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imbalance of NKG2D and its inhibitory counterparts: how does tumor escape from innate immunity?
    Zhang C; Zhang J; Wei H; Tian Z
    Int Immunopharmacol; 2005 Jul; 5(7-8):1099-111. PubMed ID: 15914316
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The inhibitory effects of synthetic short peptides, mimicking MICA and targeting at NKG2D receptors, on function of NK cells.
    Zhang B; Wei H; Zheng X; Zhang J; Sun R; Tian Z
    Peptides; 2005 Mar; 26(3):405-12. PubMed ID: 15652646
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Up-regulation of NK cell activating receptors following allogeneic hematopoietic stem cell transplantation under a lymphodepleting reduced intensity regimen is associated with elevated IL-15 levels.
    Boyiadzis M; Memon S; Carson J; Allen K; Szczepanski MJ; Vance BA; Dean R; Bishop MR; Gress RE; Hakim FT
    Biol Blood Marrow Transplant; 2008 Mar; 14(3):290-300. PubMed ID: 18275895
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NKG2D and cytotoxic effector function in tumor immune surveillance.
    Hayakawa Y; Smyth MJ
    Semin Immunol; 2006 Jun; 18(3):176-85. PubMed ID: 16675266
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Natural killer cell signaling pathways.
    Vivier E; Nunès JA; Vély F
    Science; 2004 Nov; 306(5701):1517-9. PubMed ID: 15567854
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel aspects of in vitro IL-2 or IFN-α enhanced NK cytotoxicity of healthy individuals based on NKG2D and CD161 NK cell receptor induction.
    Konjević G; Mirjačić Martinović K; Vuletić A; Radenković S
    Biomed Pharmacother; 2010 Dec; 64(10):663-71. PubMed ID: 20800424
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of major histocompatibility complex class I chain-related molecule A, NKG2D, and transforming growth factor-beta in the liver of humans with alveolar echinococcosis: new actors in the tolerance to parasites?
    Zhang S; Hüe S; Sène D; Penfornis A; Bresson-Hadni S; Kantelip B; Caillat-Zucman S; Vuitton DA
    J Infect Dis; 2008 May; 197(9):1341-9. PubMed ID: 18422447
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potentiation of NK cell-mediated cytotoxicity in human lung adenocarcinoma: role of NKG2D-dependent pathway.
    Le Maux Chansac B; Missé D; Richon C; Vergnon I; Kubin M; Soria JC; Moretta A; Chouaib S; Mami-Chouaib F
    Int Immunol; 2008 Jul; 20(7):801-10. PubMed ID: 18441340
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of interleukin-15 gene-modified human natural killer cells: implications for adoptive cellular immunotherapy.
    Zhang J; Sun R; Wei H; Zhang J; Tian Z
    Haematologica; 2004 Mar; 89(3):338-47. PubMed ID: 15020274
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cell surface organization of stress-inducible proteins ULBP and MICA that stimulate human NK cells and T cells via NKG2D.
    Eleme K; Taner SB; Onfelt B; Collinson LM; McCann FE; Chalupny NJ; Cosman D; Hopkins C; Magee AI; Davis DM
    J Exp Med; 2004 Apr; 199(7):1005-10. PubMed ID: 15051759
    [TBL] [Abstract][Full Text] [Related]  

  • 33. KHYG-1, a model for the study of enhanced natural killer cell cytotoxicity.
    Suck G; Branch DR; Smyth MJ; Miller RG; Vergidis J; Fahim S; Keating A
    Exp Hematol; 2005 Oct; 33(10):1160-71. PubMed ID: 16219538
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IL-2-activated haploidentical NK cells restore NKG2D-mediated NK-cell cytotoxicity in neuroblastoma patients by scavenging of plasma MICA.
    Kloess S; Huenecke S; Piechulek D; Esser R; Koch J; Brehm C; Soerensen J; Gardlowski T; Brinkmann A; Bader P; Passweg J; Klingebiel T; Schwabe D; Koehl U
    Eur J Immunol; 2010 Nov; 40(11):3255-67. PubMed ID: 21061445
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How NKG2D ligands trigger autoimmunity?
    Caillat-Zucman S
    Hum Immunol; 2006 Mar; 67(3):204-7. PubMed ID: 16698443
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IFN-gamma production and degranulation are differentially regulated in response to stimulation in murine natural killer cells.
    Vahlne G; Becker S; Brodin P; Johansson MH
    Scand J Immunol; 2008 Jan; 67(1):1-11. PubMed ID: 18028287
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phenotypic and functional characterization of NK cells in adenoids.
    Mizrahi S; Yefenof E; Gross M; Attal P; Ben Yaakov A; Goldman-Wohl D; Maly B; Stern N; Katz G; Gazit R; Sionov RV; Mandelboim O; Chaushu S
    J Leukoc Biol; 2007 Nov; 82(5):1095-105. PubMed ID: 17675561
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TCR-independent cytokine stimulation induces non-MHC-restricted T cell activity and is negatively regulated by HLA class I.
    von Geldern M; Simm B; Braun M; Weiss EH; Schendel DJ; Falk CS
    Eur J Immunol; 2006 Sep; 36(9):2347-58. PubMed ID: 16909431
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interaction between conventional dendritic cells and natural killer cells is integral to the activation of effective antiviral immunity.
    Andoniou CE; van Dommelen SL; Voigt V; Andrews DM; Brizard G; Asselin-Paturel C; Delale T; Stacey KJ; Trinchieri G; Degli-Esposti MA
    Nat Immunol; 2005 Oct; 6(10):1011-9. PubMed ID: 16142239
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ex vivo expansion of non-MHC-restricted cytotoxic effector cells as adoptive immunotherapy for myeloma.
    Wu JY; Ernstoff MS; Hill JM; Cole B; Meehan KR
    Cytotherapy; 2006; 8(2):141-8. PubMed ID: 16698687
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.